State GA
Clinical Trials in Georgia
Recruiting clinical trials with at least one study location in Georgia. Data updated daily from ClinicalTrials.gov.
Top Conditions in Georgia
NCT07089888 Phase 3
Recruiting
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
Condition
Tophaceous Gout
Enrollment
250 pts
Location
United States
Sponsor
Crystalys Therapeutics
NCT06719141 Phase 3
Recruiting
A Study to Investigate LP352 in Children and Adults With Developmental and Epile...
Condition
Developmental and Epileptic Encephalopathy
Enrollment
320 pts
Location
United States, Australia, Belgium
Sponsor
Longboard Pharmaceuticals
NCT05243797 Phase 3
Recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Al...
Condition
Multiple Myeloma
Enrollment
1,594 pts
Location
United States, Argentina, Australia
Sponsor
European Myeloma Network B.V.
NCT05040360 Phase 2
Recruiting
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendo...
Condition
Metastatic Malignant Neoplasm in the Liver
Enrollment
141 pts
Location
United States, Mexico, Uruguay
Sponsor
SWOG Cancer Research Network
NCT05768932 Phase 1
Recruiting
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute M...
Condition
Advanced Solid Tumor
Enrollment
260 pts
Location
United States, South Korea
Sponsor
SillaJen, Inc.
NCT05106296 Phase 1
Recruiting
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric B...
Condition
Ependymoma
Enrollment
37 pts
Location
United States
Sponsor
Theodore S. Johnson
NCT04965675 Phase 3
Recruiting
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
Condition
Chronic Migraine in Children
Enrollment
285 pts
Location
United States, Argentina, Canada
Sponsor
H. Lundbeck A/S
NCT06819007 Phase 3
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy ...
Condition
Ovarian Cancer
Enrollment
582 pts
Location
United States, Australia, Austria
Sponsor
Daiichi Sankyo
NCT06827236 Phase 1, Phase 2
Recruiting
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called...
Condition
Locally Advanced Breast Cancer
Enrollment
380 pts
Location
United States, Canada, China
Sponsor
BioNTech SE
NCT04428671 Phase 1
Recruiting
Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squ...
Condition
Metastatic Skin Squamous Cell Carcinoma
Enrollment
20 pts
Location
United States
Sponsor
Emory University
NCT05856773 Phase 3
Recruiting
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation...
Condition
Breast Cancer
Enrollment
276 pts
Location
United States
Sponsor
Proton Collaborative Group
NCT05923073 Phase 3
Recruiting
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Acti...
Condition
Crohn's Disease
Enrollment
120 pts
Location
United States, Australia, Austria
Sponsor
Janssen Research & Development
NCT05633654 Phase 3
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physic...
Condition
Triple Negative Breast Cancer
Enrollment
1,514 pts
Location
United States, Australia, France
Sponsor
Gilead Sciences
NCT03816345 Phase 1
Recruiting
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastati...
Condition
Autoimmune Disease
Enrollment
300 pts
Location
United States, Canada
Sponsor
National Cancer Institute (NCI
NCT07006792 Phase 4
Recruiting
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Modera...
Condition
Atopic Dermatitis
Enrollment
200 pts
Location
United States, Argentina, Brazil
Sponsor
Eli Lilly and Company
NCT06439836 Phase 1
Recruiting
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metast...
Condition
Metastatic Urothelial Carcinoma
Enrollment
27 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT07494305 Phase 2
Recruiting
Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment o...
Condition
Bipolar I Disorder
Enrollment
320 pts
Location
United States
Sponsor
LB Pharmaceuticals Inc.
NCT06088290 Phase 3
Recruiting
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone ...
Condition
Leiomyosarcoma
Enrollment
450 pts
Location
United States, Austria, Belgium
Sponsor
PharmaMar
NCT04620239 Phase 3
Recruiting
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTE...
Condition
Transitional Cell Cancer of Renal Pelvis and Ureter
Enrollment
100 pts
Location
United States, France, Germany
Sponsor
Steba Biotech S.A.
NCT06856577 Phase 3
Recruiting
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants ...
Condition
Neovascular Age-Related Macular Degeneration (nAMD)
Enrollment
284 pts
Location
United States
Sponsor
Adverum Biotechnologies, Inc.
NCT06462612 Phase 3
Recruiting
Study of Lumateperone in the Treatment of Patients With Bipolar Mania
Condition
Bipolar Disorder, Manic
Enrollment
350 pts
Location
United States, Bulgaria, Romania
Sponsor
Intra-Cellular Therapies, Inc.
NCT05757102 Phase 3
Recruiting
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/V...
Condition
Asthma
Enrollment
292 pts
Location
United States, Argentina, Australia
Sponsor
GlaxoSmithKline
NCT06430164 N/A
Recruiting
AB Gait Estim Neurophysiology
Condition
Gait
Enrollment
50 pts
Location
United States
Sponsor
Emory University
NCT04634552 Phase 2
Recruiting
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myel...
Condition
Hematological Malignancies
Enrollment
510 pts
Location
United States, Belgium, China
Sponsor
Janssen Research & Development
NCT06679985 Phase 2
Recruiting
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Part...
Condition
Hepatocellular Carcinoma
Enrollment
72 pts
Location
United States, Australia, Canada
Sponsor
Coherus Oncology, Inc.